Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (12) | Back to Search
Innovation in biologics drug product development & manufacture
- In: Symposium C1: Innovative Production Technologies for Biologics on Monday, 22 May 2017, 15:00-15:35
- At: Stockholm (Sweden) (2017)
- Type: Presentation
- By: MAHLER, Hanns-Christian (Lonza AG, Drug Product Services, Basel, Switzerland)
- Co-author(s): Hanns-Christian Mahler: Drug Product Services, Lonza AG, Basel, Switzerland
- Abstract:
To date, Biologics account for one third of annual approvals. Biologics generally have to be administered by parenteral administration (injection, infusion or implant) in order to achieve adequate systemic exposure and thus, ensure efficacy and safety, whilst ensuring efficient costs. Biologics include molecules derived from recombinant
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023